TAO Synergies (TAOX) Consolidated Net Income (2019 - 2026)
TAO Synergies' (TAOX) quarterly Consolidated Net Income came in at -$9.3 million in Q2 2026, up 46.91% on a YoY basis from -$6.3 million in Q2 2025, and down 318.57% quarter-over-quarter from $4.3 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Consolidated Net Income (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Consolidated Net Income for 8 consecutive years, with -$9.3 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Consolidated Net Income rose 46.91% year-over-year to -$9.3 million; the trailing twelve-month figure through Jun 2026 stood at -$16.7 million (up 41.41% YoY), and the FY2025 full-year result was -$22.7 million, down 125.06% from the prior year.
- Consolidated Net Income eased to -$9.3 million in Q2 2026 per TAOX's latest filing, from $4.3 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $4.5 million in Q4 2022 and bottomed at -$17.5 million in Q2 2025.
- Historically, Consolidated Net Income has averaged -$3.2 million across 5 years, with a median of -$3.2 million in 2022.
- The sharpest annual moves came in 2025 and 2026: Consolidated Net Income plunged 1275.63% in 2025, then soared 1004.55% in 2026.
- Over 5 years, Consolidated Net Income stood at $4.5 million in 2022, then tumbled by 122.22% to -$995969.0 in 2023, then sank by 456.9% to -$5.5 million in 2024, then sank by 38.52% to -$7.7 million in 2025, then declined by 21.03% to -$9.3 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$9.3 million, $4.3 million, and -$7.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn | -290.61 Mn |
| 10 | TAO Synergies | 30.41 Mn | 30.41 Mn | - | -9.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.30 Mn |
| Mar 31, 2026 | 4.25 Mn |
| Dec 31, 2025 | -7.68 Mn |
| Sep 30, 2025 | -3.92 Mn |
| Jun 30, 2025 | -17.52 Mn |
| Mar 31, 2025 | 385,169.00 |
| Dec 31, 2024 | -5.55 Mn |
| Sep 30, 2024 | -5.74 Mn |
| Jun 30, 2024 | -1.27 Mn |
| Mar 31, 2024 | -206,699.00 |
| Dec 31, 2023 | -995,969.00 |
| Sep 30, 2023 | 763,203.00 |
| Jun 30, 2023 | -4.09 Mn |
| Mar 31, 2023 | -1.71 Mn |
| Dec 31, 2022 | 4.48 Mn |
| Sep 30, 2022 | -3.03 Mn |
| Jun 30, 2022 | -3.75 Mn |
| Mar 31, 2022 | -3.28 Mn |
| Dec 31, 2021 | -4.24 Mn |
| Sep 30, 2021 | -2.93 Mn |